Magazine Article | January 4, 2022

Will Pyxis Oncology Be Pfizer's Fourth Billion-Dollar Spinout?

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

It was late 2015 when Lara Sullivan, M.D., first called me. At the time she was a VP at Pfizer and working closely with Freda Lewis-Hall, M.D., then the company’s chief medical officer. From their vantage point, they could see this tremendous pipeline flow of assets—along with what got funded — and what did not. “There were a number of programs that had great clinical data, but unfortunately, did not have a development path within Pfizer,” she elaborates.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: